Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

• Main Authors: Mamta K. Jain (Author), James A. De Lemos (Author), Darren K. McGuire (Author), Colby. Ayers (Author), Jennifer L. Eitson (Author), Claudia L. Sanchez (Author), Dena Kamel (Author), Jessica A. Meisner (Author), Emilia V. Thomas (Author), Anita A. Hegde (Author), Satish Mocherla (Author), Joslyn K. Strebe (Author), Xilong Li (Author), Noelle S. Williams (Author), Chao Xing (Author), Mahmoud S. Ahmed (Author), Ping Wang (Author), Hesham A. Sadek (Author), John W. Schoggins (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: An in silico screen was performed to identify FDA approved drugs that inhibit SARS-CoV-2 main protease (Mpro), followed by in vitro viral replication assays, and in vivo pharmacokinetic studies in mice. These studies identified atovaquone as a promising candidate for inhibiting viral rep...